Scientific Sessions
  • #AHA22
  • Virtual Experience Access
  • Sessions Posters
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Featured Exhibitors
  • Program
  • Previews
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Featured Exhibitors
  • Program
  • Previews
Resources
  • #AHA22
  • Virtual Experience Access
  • Sessions Posters
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter iconFacebook iconInstagram iconYouTube iconPinterest iconLinkedIn icon
Nov 13th, 2021

Managing the Heart Failure Patient with Reduced Ejection Fraction: New Perspectives and Emerging Evidence

Experts discuss the need to personalize treatment of heart failure with reduced ejection fraction (HFrEF), explain evidence with therapy to improve contractility and outcomes, and describe best practices for treating worsening HF.


Screenshot 2021 11 02 134539

A central factor in the pathogenesis of heart failure (HF) with reduced ejection fraction (HFrEF) is the initial decrease in systolic function.  Pharmacological agents that improve myocardial performance can be categorized based on 3 myocardial mechanisms: calcitropes, which alter intracellular calcium concentrations; myotropes, which affect the molecular motor and scaffolding; and mitotropes, which influence energetics.  Omecamtiv mecarbil, an investigational therapy which improves contraction by a novel mechanism of action, has demonstrated a reduction in the risk of a composite of a first heart failure event or cardiovascular death, with an excellent safety and tolerability profile. 

New therapies are becoming available for the treatment of HFrEF, providing the clinician with more opportunities for an individualized approach to pharmacotherapy.  Patients with worsening HF are particularly challenging; guideline-directed medical therapy (GDMT) often cannot be optimized in these patients due to a variety of factors (such as multiple organ system involvement, lower glomerular filtration rate, higher risk of hyperkalemia, lower systolic blood pressure, and higher risk of medication side effects/intolerance).  There is an unmet need for new therapies to improve ventricular performance and clinical outcomes in this difficult-to-treat patient population. In this program, HF experts will provide insights into mechanisms for improving myocardial contractility and clinical evidence and emphasize the need for a more personalized treatment of HFrEF.  A case discussion will illustrate current best practices for managing patients with worsening HF, and identify a potential role for emerging therapies.

Saturday, November 13, 2021
5:30 pm to 7:00 pm Eastern Standard Time and OnDemand

Presenters:
Gregg Fonarow, MD (Chair)
Interim Chief, UCLA Division of Cardiology
Eliot Corday Chair in Cardiovascular Medicine and Science
Professor of Medicine
David Geffen School of Medicine at UCLA, Los Angeles, California

Scott Solomon, MD
The Edward D. Frohlich Distinguished Chair
Professor of Medicine
Harvard Medical School, Boston, Massachusetts

John Teerlink, MD
Professor of Medicine
University of California, San Francisco School of Medicine
Director of Heart Failure
San Francisco Veterans Affairs Medical Center, San Francisco, California

Jane Wilcox, MD, MSc
Associate Professor of Medicine
Northwestern University Feinberg School of Medicine; Chicago, Illinois

This activity is supported by an independent educational grant from Cytokinetics Incorporated.

This event is not part of the official Scientific Sessions as planned by the AHA Committee on Scientific Sessions Programming.

The American Heart Association (AHA) does not endorse any commercial products or programs. The links provided within this site are for convenience only, and are not an endorsement of either the linked-to entity, product or service.  AHA makes no warranties of any kind, express or implied, with regard to its third-party vendor websites.

Download
Interesting Stories
Modern Wearable Defibrillation
Sponsored by Kestra Medical Technologies
Modern Wearable Defibrillation
Data-driven precision medicine
Sponsored by Tempus
Data-driven precision medicine
New Double Take Videos from NEJM
Sponsored by NEJM Group
New Double Take Videos from NEJM
MiCare Path joins the AHA CHTI and will integrate AHA science-based
Sponsored by MiCare Path
MiCare Path joins the AHA CHTI and will integrate AHA science-based
More Content
Screenshot 2021 11 02 130142
Sponsored Content
Antiplatelet Therapy in Patients With Coronary Artery Disease and Acute Ischemic Stroke/Transient Ischemic Attack
Oct 4th, 2022
Getty Images 1180201381
Daily Coverage
Join the Scientific Sessions 2022 Scavenger Hunt
Aug 15th, 2022
Live Meeting Image
AHA21
Member Connect
Dec 13th, 2021
P104 Steven Botts Image
AHA21
Members Connect: ERG Governs Chromatin Accessibility in Aortic Endothelial Cells
Dec 13th, 2021
Pres Address Lloyd Jones2
AHA21
Watch: #AHA21 recap and look ahead
Nov 22nd, 2021
Getty Images 1301907602
AHA21
Mark your calendar for #AHA22
Nov 19th, 2021
Elaine Hylek, MD, MPH, and Bruno Caramelli, MD, PhD
AHA21
Trials’ results suggest advancements in treatment approaches for AF and insight on the cardiac effects of coffee consumption
Nov 19th, 2021
Lbs02 Group Blood Patel
AHA21
Update on local and global hypertension science
Nov 19th, 2021
Getty Images 1219980553 61849bc953192
AHA21
Read all about #AHA21 in your daily coverage
Nov 16th, 2021
(from left to right): Brahmajee K. Nallamothu, MD, MPH, FAHA, Rhoda Au, PhD, Seth Martin, MD, MHS, FAHA, and Andrea Beaton, MD, FAHA
AHA21
QCOR at Sessions: mHealth strategies could help treat CVD around the world
Nov 15th, 2021
(from left to right, top to bottom rows): Corey E. Ventetuolo, MD, MS, Magdi Yacoub, OM, FRS, Karen Joynt Maddox, MD, MPH, FAHA, Gregory Lewis, MD, Marco Guazzi, MD, PhD, FAHA, Ana Macumbi, MD, PhD, FESC, Mark T. Gladwin, MD, FAHA, and William Bain, MD
AHA21
The shifting profile of cardiopulmonary COVID-19 survivors
Nov 15th, 2021
(from left to right): Jonathan P. Piccini, MD, MHS, FAHA, and Steven A. Lubitz, MD, MPH, FAHA
AHA21
Late-Breaking Science: New information in cardiac disease
Nov 15th, 2021